Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 9, Issue 5, 2009, Pages 214-217

  Hackett, Geoffrey I ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Erectile dysfunction; Hypogonadism; NICE; Quality Outcome Framework; Type 2 diabetes

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; CANCER RISK; CARDIOVASCULAR RISK; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HORMONAL REGULATION; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM;

EID: 74549139064     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651409340361     Document Type: Review

References (25)

1. Home P, Mant J, Diaz J, Turner C. On behalf of the Guideline Development Group Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008;336:1306-1308
2. Hackett G, Kell P, Ralph D et al. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction. J Sex Med 2008;5:1841-1846
3. Wespes E, Amar E, Hatzichristou DG et al. EAU guidelines on erectile. dysfunction. Eur Urol 2002;41:1-5.
4. Kapoor D, Aldred H, Clark S et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-917
5. Connecting for Health: the 2004 GP contract. www.nhs.org.uk
6. Dhindsa S, Prabhakar S, Sethi M et al. Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. J Clin End Metab 2004;89:5462-5468
7. Isidori AM, Caprio M, Strollo F et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-3680
8. Andersson B, Marin P, Lissner L et al. Testosterone concentrations in women and men with NIDDM . Diabetes Care 1994;17:405-411
9. Ozata M, Oktenli C, Cagatay O, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res 2001;9:662-667
10. Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care 2002;25:55-60.
11. Shores MM, Matsumoto AM, Sloan KL et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-1665
12. Khaw KT, Dowsett M, Folkerd E et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPICNorfolk) prospective population study. Circulation 2007;116:2694-2701
13. Billups KL. Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005;17(suppl 1):S19-24.
14. Gazzaruso C, Solerte SB, Pujia A et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease. J Am Coll Cardiol 2008;51:2040-2044
15. Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002.
16. Montorsi F, Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-365
17. Ma RCW, So WY, Yang XL et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008;51: 2045-2050
18. Rader DJ. Effect of insulin resistance, dyslipidemia, and the intraabdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120:512-518
19. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-99
20. Shabsigh R, Kaufman J, Steidle J et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men who do not respond to sildenafil alone. J Urol 2004;172: 658-663
21. Kapoor D, Goodwin E, Channer KS et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
22. Kapoor D, Clarke S, Stanworth R et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007;156: 595-602.
23. Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 2007;13:629-635
24. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
25. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009;21:9-23.